A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy
Authors:
- Bruno AudhuyBABruno Audhuy
- Paul CappelaerePCPaul Cappelaere
- Miquel MartínMMMiquel Martín
- Andrés CervantesAndrés Cervantes
- Michel FabbroMFMichel Fabbro
- Alain RivièreARAlain Rivière
- David KhayatDKDavid Khayat
- Harry BleibergHBHarry Bleiberg
- Marc FaraldiMFMarc Faraldi
- Nicole ClaverieNCNicole Claverie
- 1 May 1996
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 32 (5) , 807-813
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Control of Chemotherapy-Induced EmesisNew England Journal of Medicine, 1993
- Current issues in the management of nausea and vomitingAnnals of Oncology, 1993
- The impact of cytotoxic chemotherapy - perspectives from patients, specialists and nursesEuropean Journal of Cancer, 1992
- Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapyCancer, 1992
- 5-HT3 Receptor AntagonistsDrugs, 1991
- Serotonin Antagonists: A New Class of Antiemetic AgentsJNCI: Journal of the National Cancer Institute, 1991
- Comparison of the 5-Hydroxytryptamine3(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced EmesisNew England Journal of Medicine, 1990
- Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting.Journal of Clinical Oncology, 1989
- Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy.Journal of Clinical Oncology, 1985
- Nausea and Vomiting as Major Complications of Cancer ChemotherapyDrugs, 1983